Establishment and Multidimensional Pathological Evaluations of a Cigarette Smoke Exposure-Induced Chronic Obstructive Pulmonary Disease Mouse Model

doi:10.12300/j.issn.1674-5817.2025.076

Abstract

Abstract:

Objective To establish a reliable chronic obstructive pulmonary disease (COPD) mouse model based on a self-developed multichannel automatic control system for long-term continuous cigarette smoke exposure in small animals using a novel continuous cigarette smoke exposure method, and to conduct phenotypic evaluation and analysis, thereby providing an animal experimental basis for investigating COPD pathogenesis and prevention strategies. Methods Twenty male C57BL/6J mice aged 6 weeks were randomly and equally divided into a control group and a model group. The model group (n=10) underwent 6 h of continuous cigarette smoke exposure daily (6 cigarettes per day for 12 consecutive weeks), while the control group (n=10) received no intervention. Body weight was monitored biweekly. Post-exposure, in vivo micro-CT imaging was performed. After euthanasia, serum and bronchoalveolar lavage fluid (BALF) levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were quantified by ELISA. Lung tissues underwent H&E and Masson's trichrome staining to observe changes in lung morphology and inflammatory cell infiltration, and the mean linear intercept (MLI) was calculated, thereby comprehensively evaluating the clinical features of COPD in the mouse model. Results Compared with the control group, the model group showed significantly reduced body weight (P<0.01) from the fourth week. Compared with the control group, IL-6 level in the serum and BALF of the model group increased by 27.2% and 140.0%, respectively (P<0.01). TNF-α level in the serum and bronchoalveolar lavage fluid of the model group increased by 16.7% (P<0.01) and 19.3% (P<0.05), respectively. Histopathological examination revealed alveolar wall thinning, septal rupture, emphysematous bullae formation, reduced alveolar count, bronchial wall thickening with lumen narrowing, and inflammatory cell infiltration. MLI was significantly elevated (P<0.01). Masson's staining confirmed collagen deposition and bronchial remodeling. Micro-CT demonstrated localized high-density shadows exhibiting typical features of chronic bronchitis. Conclusion The self-developed device enables long-term continuous smoke exposure, and the successfully established COPD mouse model exhibits pathological features highly consistent with clinical manifestations, offering an efficient and reliable tool for COPD research.

Key words: Chronic obstructive pulmonary disease, Cigarette smoke exposure, Mouse model, Self-developed device, Continuous exposure

CLC Number:

Q95-33

HE Jiaqi,ZHOU Yuanyuan,NIE Yongqiang,et al. Establishment and Multidimensional Pathological Evaluations of a Cigarette Smoke Exposure-Induced Chronic Obstructive Pulmonary Disease Mouse Model[J]. Laboratory Animal and Comparative Medicine, 2026, 46(1): 11-19. DOI: 10.12300/j.issn.1674-5817.2025.076.

Figures/Tables 5

References 31

[1]	VOGELMEIER C F, ROMÁN-RODRÍGUEZ M, SINGH D, et al. Goals of COPD treatment: Focus on symptoms and exacerbations[J]. Respir Med, 2020, 166:105938. DOI:10.1016/j.rmed.2020.105938 .
[2]	PATEL N. An update on COPD prevention, diagnosis, and management: The 2024 GOLD Report[J]. Nurse Pract, 2024, 49(6):29-36. DOI:10.1097/01.NPR.0000000000000180 .
[3]	CHRISTENSON S A, SMITH B M, BAFADHEL M, et al. Chronic obstructive pulmonary disease[J]. Lancet, 2022, 399(10342):2227-2242. DOI:10.1016/S0140-6736(22)00470-6 .
[4]	李丽球, 谢丽华, 孙圣华. 慢性阻塞性肺疾病动物模型的研究进展[J]. 中南大学学报(医学版), 2017, 42(9):1105-1110. DOI: 10.11817/j.issn.1672-7347.2017.09.018 .
	LI L Q, XIE L H, SUN S H. Progress in study on animal models of chronic obstructive pulmonary disease[J]. J Cent South Univ Med Sci, 2017, 42(9):1105-1110. DOI: 10.11817/j.issn.1672-7347.2017.09.018 .
[5]	FU Y S, KANG N, YU Y P, et al. Polyphenols, flavonoids and inflammasomes: the role of cigarette smoke in COPD[J]. Eur Respir Rev, 2022, 31(164):220028. DOI:10.1183/16000617.0028-2022 .
[6]	VOYNOW J A, SHINBASHI M. Neutrophil elastase and chronic lung disease[J]. Biomolecules, 2021, 11(8):1065. DOI:10.3390/biom11081065 .
[7]	VAN DIJK E M, CULHA S, MENZEN M H, et al. Elastase-induced parenchymal disruption and airway hyper responsiveness in mouse precision cut lung slices: toward an ex vivo COPD model[J]. Front Physiol, 2017, 7:657. DOI:10.3389/fphys.2016.00657 .
[8]	BOREL F, SUN H M, ZIEGER M, et al. Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema[J]. Proc Natl Acad Sci USA, 2018, 115(11):2788-2793. DOI:10.1073/pnas.1713689115 .
[9]	ROBERTONI F S Z, VELOSA A P P, OLIVEIRA L M, et al. Type V collagen-induced nasal tolerance prevents lung damage in an experimental model: new evidence of autoimmunity to collagen V in COPD[J]. Front Immunol, 2024, 15:1444622. DOI:10.3389/fimmu.2024.1444622 .
[10]	UPADHYAY P, WU C W, PHAM A, et al. Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease (COPD)[J]. J Toxicol Environ Health B Crit Rev, 2023, 26(5):275-305. DOI:10.1080/10937404.2023.2208886 .
[11]	PELLEGRINO R, VIEGI G, BRUSASCO V, et al. Interpretative strategies for lung function tests[J]. Eur Respir J, 2005, 26(5):948-968. DOI:10.1183/09031936.05.00035205 .
[12]	张迪, 管宇, 夏艺, 等. 慢性阻塞性肺疾病动物模型研究进展[J]. 第二军医大学学报, 2018, 39(3):302-307. DOI:10.16781/j.0258-879x.2018.03.0302 .
	ZHANG D, GUAN Y, XIA Y, et al. Advances in animal models of chronic obstructive pulmonary disease[J]. Acad J Second Mil Med Univ, 2018, 39(3):302-307. DOI:10.16781/j.0258-879x.2018.03.0302 .
[13]	马宏境, 刘彬. 慢性阻塞性肺疾病发病机制的研究[J]. 医学信息, 2019, 32(10):50-52. DOI: 10.3969/j.issn.1006-1959.2019.10.018 .
	MA H J, LIU B. Study on the pathogenesis of chronic obstructive pulmonary disease[J]. Med Inf, 2019, 32(10):50-52. DOI: 10.3969/j.issn.1006-1959.2019.10.018 .
[14]	罗玉馨, 胡晓佳, 曹竟尹, 等. 慢性阻塞性肺疾病动物模型的研究与开发[J]. 黑龙江科学, 2022, 13(18): 14-16. DOI:10.3969/j.issn.1674-8646.2022.18.004 .
	LUO Y X, HU X J, CAO J Y, et al. Research and development of animal model of chronic obstructive pulmonary disease[J]. Heilongjiang Sci, 2022, 13(18): 14-16. DOI:10.3969/j.issn.1674-8646.2022.18.004 .
[15]	LÜTHJE L, RAUPACH T, MICHELS H, et al. Exercise intolerance and systemic manifestations of pulmonary emphysema in a mouse model[J]. Respir Res, 2009, 10(1):7. DOI:10.1186/1465-9921-10-7 .
[16]	STEVENSON C S, BIRRELL M A. Moving towards a new generation of animal models for asthma and COPD with improved clinical relevance[J]. Pharmacol Ther, 2011, 130(2):93-105. DOI:10.1016/j.pharmthera.2010.10.008 .
[17]	WRIGHT J L, COSIO M, CHURG A. Animal models of chronic obstructive pulmonary disease[J]. Am J Physiol Lung Cell Mol Physiol, 2008, 295(1): L1-L15. DOI:10.1152/ajplung.90200.2008 .
[18]	TOLEDO A C, MAGALHAES R M, HIZUME D C, et al. Aerobic exercise attenuates pulmonary injury induced by exposure to cigarette smoke[J]. Eur Respir J, 2012, 39(2):254-264. DOI:10.1183/09031936.00003411 .
[19]	GASCHLER G J, BAUER C M T, ZAVITZ C C J, et al. Animal models of chronic obstructive pulmonary disease exacerbations[J]. Contrib Microbiol, 2007, 14:126-141. DOI:10.1159/000107059 .
[20]	GONG G, SHEN S P, SHEN S R, et al. YAP/TAZ-mediated nuclear membrane rupture in promoting senescence of skeletal muscle associated with COPD[J]. Respir Res, 2025, 26(1):98. DOI:10.1186/s12931-025-03170-4 .
[21]	KOGEL U, WONG E T, SZOSTAK J, et al. Impact of whole-body versus nose-only inhalation exposure systems on systemic, respiratory, and cardiovascular endpoints in a 2-month cigarette smoke exposure study in the ApoE mouse model[J]. J Appl Toxicol. 2021 Oct;41(10):1598-1619. DOI: 10.1002/jat.4149 .
[22]	梁小波, 吴德洪, 王星, 等. 鼻内滴注烟草提取物和脂多糖建立慢性阻塞性肺疾病小鼠模型的评价[J]. 吉林大学学报(医学版), 2019, 45(6):1454-1458, 1486. DOI:10.13481/j.1671-587x.20190645 .
	LIANG X B, WU D H, WANG X, et al. Evaluation on mouse models of chronic obstructive pulmonary disease induced by intranasal instillation of cigarette smoke extract and lipopolysaccharide[J]. J Jilin Univ Med Ed, 2019, 45(6):1454-1458, 1486. DOI:10.13481/j.1671-587x.20190645 .
[23]	HIGASHI T, MAI Y, MAZAKI Y, et al. A standardized method for the preparation of a gas phase extract of cigarette smoke[J]. Biol Pharm Bull, 2016, 39(6):898-902. DOI:10.1248/bpb.b16-00062 .
[24]	LI W J, LI Y Y, WANG Q, et al. Therapeutic effect of phycocyanin on chronic obstructive pulmonary disease in mice[J]. J Adv Res, 2024, 66:285-301. DOI:10.1016/j.jare. 2024.01.009 .
[25]	PELGRIM C E, WANG L, PERALTA MARZAL L N, et al. Increased exploration and hyperlocomotion in a cigarette smoke and LPS-induced murine model of COPD: linking pulmonary and systemic inflammation with the brain[J]. Am J Physiol Lung Cell Mol Physiol, 2022, 323(3): L251-L265. DOI:10.1152/ajplung.00485.2021 .
[26]	陈亚红. 2022年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J]. 中国全科医学, 2022, 25(11): 1294-1304, 1308.
	CHEN Y H. Interpretation of global strategy for the diagnosis, treatment, management and prevention of chronic obstructive pulmonary disease 2022 report[J]. Chin Gen Pract, 2022, 25(11):1294-1304, 1308. DOl:10.12114/j.issn.1007-9572.2022.01.302.
[27]	KANG S J, NARAZAKI M, METWALLY H, et al. Correction: Historical overview of the interleukin-6 family cytokine[J]. J Exp Med, 2020, 217(5):jem.2019034704212020c. DOI:10.1084/jem.2019034704212020c .
[28]	YUK J M, KIM J K, KIM I S, et al. TNF in human tuberculosis: a double-edged sword[J]. Immune Netw, 2024, 24(1): e4. DOI:10.4110/in.2024.24.e4 .
[29]	XU J, ZENG Q Y, LI S Q, et al. Inflammation mechanism and research progress of COPD[J]. Front Immunol, 2024, 15:1404615. DOI:10.3389/fimmu.2024.1404615 .
[30]	GUO P, LI R, PIAO T H, et al. Pathological mechanism and targeted drugs of COPD[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17:1565-1575. DOI:10.2147/COPD.S366126 .
[31]	夏艺. 大气细颗粒物(PM_2.5) 暴露大鼠肺部微结构改变的影像研究[D]. 上海: 中国人民解放军海军军医大学, 2021. DOI:10.26998/d.cnki.gjuyu.2021.000087 .
	XIA Y. Imaging study of lung microstructure changes exposure to ambient air fine particulate matter (PM_2.5) induces lung injury in rats[D]. Shanghai: Naval Medical University, 2021. DOI:10.26998/d.cnki.gjuyu.2021.000087 .